A Randomized Trial of Modified-Release Versus Immediate-Release Tolvaptan in ADPKD
Authors:
Open Access
- 1 June 2020
- journal article
- research article
- Published by Elsevier in Kidney International Reports
- Vol. 5 (6) , 790-800
Abstract
No abstract availableKeywords
Funding Information
- Otsuka Pharmaceutical Development & Commercialization
This publication has 15 references indexed in Scilit:
- Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney DiseaseNew England Journal of Medicine, 2012
- Dosing Frequency and Medication Adherence in Chronic DiseaseJournal of Managed Care Pharmacy, 2012
- Evaluation of urgency in women, with a validated Urgency, Severity and Impact Questionnaire (USIQ)International Urogynecology Journal, 2008
- Cyclic AMP promotes growth and secretion in human polycystic kidney epithelial cellsKidney International, 2004
- Cyclic AMP, at the hub of the cystic cycleKidney International, 2004
- Development and validation of a quality-of-life measure for men with nocturiaUrology, 2004
- Effective treatment of an orthologous model of autosomal dominant polycystic kidney diseaseNature Medicine, 2004
- cAMP stimulates the in vitro proliferation of renal cyst epithelial cells by activating the extracellular signal-regulated kinase pathwayKidney International, 2000
- A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAnnals of Internal Medicine, 1999
- Evaluation of ultrasonographic diagnostic criteria for autosomal dominant polycystic kidney disease 1The Lancet, 1994